Cytomegalovirus (CMV) retinitis is among the most common opportunistic infections in patients with acquired immunodeficiency syndrome. In a prospective study of 210 patients with CMV retinitis, 26 were identified as having either a phenotypic or a genotypic ganciclovirresistant isolate from either blood or urine cultures. For blood culture isolates with an IC 50 16.0 mm for ganciclovir, the sensitivity and specificity for detecting a UL97 mutation were 95% and 98%, respectively, whereas for an IC 50 18.0 mM they were 79% and 99%, respectively. Although there were trade-offs between the 2 thresholds for blood culture isolates, for urine culture isolates an IC 50 18.0 mM appeared to be better at identifying genotypic resistance. UL97 mutations identified in both the blood and urine cultures of individual patients were identical in 87.5% of cases. High-level ganciclovir resistance (IC 50 , 130 mM) typically, but not invariably, was associated with a mutation in both the UL97 and UL54 genes.
Cytomegalovirus (CMV) retinitis is among the most common opportunistic infections in patients with acquired immunodeficiency syndrome. In a prospective study of 210 patients with CMV retinitis, 26 were identified as having either a phenotypic or a genotypic ganciclovirresistant isolate from either blood or urine cultures. For blood culture isolates with an IC 50 16.0 mm for ganciclovir, the sensitivity and specificity for detecting a UL97 mutation were 95% and 98%, respectively, whereas for an IC 50 18 .0 mM they were 79% and 99%, respectively. Although there were trade-offs between the 2 thresholds for blood culture isolates, for urine culture isolates an IC 50 18 .0 mM appeared to be better at identifying genotypic resistance. UL97 mutations identified in both the blood and urine cultures of individual patients were identical in 87.5% of cases. High-level ganciclovir resistance (IC 50 , 130 mM) typically, but not invariably, was associated with a mutation in both the UL97 and UL54 genes.
Cytomegalovirus (CMV) retinitis is the most common intraocular infection in patients with AIDS [1] . Untreated, CMV retinitis is a progressive disease, which results in total retinal destruction and blindness [1] . As of September 2000, 4 drugs have been approved by the US Food and Drug Administration for the treatment of CMV retinitis: ganciclovir, foscarnet, cidofovir, and fomivirsen, of which ganciclovir is used most frequently. All anti-CMV agents suppress viral replication but do not eliminate CMV; therefore, unless immune reconstitution occurs, chronic suppressive maintenance therapy is required.
Patients on chronic anti-CMV therapy may develop resistant virus, and resistant CMV has been associated with poor response to therapy [2] [3] [4] . The rate of resistant CMV is approximately one-fourth to one-third by 9 months of therapy and is similar for ganciclovir, foscarnet, and cidofovir [3, 4] . Phenotypic resistance to an anti-CMV agent is defined by an IC 50 greater than a threshold level; for ganciclovir, the IC 50 threshold level typically is 6.0 mM [2, 3, 5, 6] . Genotypic resistance is defined as the occurrence of a resistance-conferring mutation. Low-level ganciclovir resistance is associated with mutations in the CMV UL97 gene, whereas high-level ganciclovir resistance is associated with mutations in both the UL97 and the UL54 genes [7] [8] [9] [10] [11] .
The CMV Retinitis and Viral Resistance Study is a prospective study of the occurrence of resistant CMV in patients with AIDS who are being treated for CMV retinitis [6] . We previously reported the frequent occurrence of resistance among patients treated for prolonged periods of time with anti-CMV agents [3, 4] . Here we report phenotype-genotype correlations for ganciclovir resistance.
Patients and Methods
Patients. Eligible patients were untreated for CMV retinitis. Enrollment and follow-up procedures have been published elsewhere [3, 4, 6] . Cultures of blood and urine for CMV were performed at enrollment (before beginning therapy), at 1 and 3 months after enrollment, every 3 months thereafter, and whenever there was clinical evidence of retinitis progression. All positive cultures were submitted for susceptibility testing. Patients were treated with standard treatment regimens, as described elsewhere [3, 4, 6] .
Phenotypic susceptibility. All positive cultures were tested for susceptibility to ganciclovir, using the Hybriwix probe system/CMV susceptibility test kit (Diagnostic Hybrids) [3, 4, 6] . Genotypic testing. DNA was extracted from CMV culture isolates using the QIAamp DNA Mini Kit (Qiagen). All CMV isolates were tested for UL97 mutations M460V, A594V, L595S, and L595F, according to the screening method of Chou et al. [12] . Sequence analysis was performed for isolates with a UL97 mutation detected by the screening assay, for isolates with an mM IC 1 6.0 50 and no mutation detected by screening, and for a sensitive isolate from each patient. The UL97 region from nt 1299-2050 was amplified by using primers 5 -GGCGTGCATCGACAGCTACCG-3 (forward) and 5 -TGCTGGTGGTGCGCCGAAAGG-3 (reverse). The amplification reaction mixture (50 mL) contained 10 mM TrisHCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin, 200 mM each dNTP, 0.5 pmol each primer, and 1.25 U AmpliTaq7 DNA polymerase (PE Applied Biosystems). Polymerase chain reaction (PCR) assays were done at 95ЊC for 10 min and then, for 35 cycles, at 95ЊC for 1 min, 60ЊC for 2 min, and 72ЊC for 1 min, followed by 72ЊC for 10 min. The amplification primers and internal CPT 1619, CPT 1713, and 1830M primers from the screening assay were used for sequencing.
Amplification of the 3.7-kb UL54 coding sequence was performed using the GeneAmp XL PCR kit (PE Applied Biosystems) and primers flanking the pol coding region, as described by Chou et al. [13] . Sequencing was performed with the 2 amplification primers and the 25 internal primers, pol 1-18, 20-23, 25, 26, and 28 (sequences provided by M. Brytting, Swedish Institute for Infectious Disease Control, Karolinske Institute, Stockholm). The pol 1-4 primer sequences have been published elsewhere [14] . The remaining sequences are listed in figure 1 . In all cases, UL97 and UL54 amplification products were purified and sequenced, without cloning, using the dRhodamine Terminator Ready Reaction kit (PE Applied Biosystems). Fluorescent-labeled sequence products were separated on a 5% polyacrylamide gel run on an ABI PRISM 377 DNA sequencer (PE Applied Biosystems). The UL97 and UL54 sequences from patients' isolates were aligned, by computer analysis, with that of AD169, to determine the presence of mutations.
Statistics. Means, medians, and frequencies were calculated to describe the study population and the subpopulation with phenotypic or genotypic resistance to ganciclovir. Conditional frequencies were calculated to describe associations between phenotypic and genotypic resistance to ganciclovir.
Results

Study population. This report includes data collected from
November 1993 through November 1999. Characteristics of the study population are shown in table 1. The subset of patients with ganciclovir resistance was similar to that of the entire population, except that the mean follow-up appeared to be longer for those who developed ganciclovir resistance. Phenotypic (IC 50 , 16 .0 mM) or genotypic resistance to ganciclovir was identified in a blood or urine culture isolate from 26 patients. Twenty-one of these patients were being treated with ganciclovir at the time that resistance was detected. Three patients had isolates with an IC 50 between 6.0 and 8.2 mM for ganciclovir while being treated with cidofovir, and 2 patients had baseline urine culture isolates with an IC 50 of 6.2 and 6.9 mM, respectively.
UL97 mutations.
Nine different UL97 mutations were identified. Seven had been confirmed to confer ganciclovir resistance in marker-transfer experiments [11] : A594V (7 patients), H520Q (4 patients), L595S (3 patients), M460V (2 patients), C592G (2 patients), L595W (1 patient), and C603W (2 patients). One point mutation, H469Y, which has not been evaluated by marker-transfer experiments, was identified in 1 patient with phenotypic resistance in both blood (IC 50 , 6.1 mM) and urine culture isolates (IC 50 , 25.8 mM). A deletion of codons 600 and 601 in the UL97 gene was identified in 1 patient with high-level ganciclovir resistance (IC 50 , 130.0 mM) in the presence of a known ganciclovir-resistance-conferring UL97 point mutation. For most patients with UL97 mutations, only 1 mutation was found in a given isolate. However, 1 patient had 2 mutations (A594V and C603W) in a single isolate, which was either a mixed population or a single population with 2 mutations. Another patient had 2 mutations (M460V and A594V) detected from the blood samples obtained at both 7 and 9 months of treatment. At 11 months of treatment, only the M460V mutation was identified in the blood, and the A594V mutation was present in the urine, which suggested a mixed population. This patient was 1 of 10 patients for whom UL97 mutations were found in sequential isolates. For all 6 of the other patients, the same mutation was persistent throughout. In 3 cases, there appeared to be a change in the mutation. There were 8 cases in which UL97 mutations were identified in both the blood and urine culture isolates from the same patient. In 7 of these 8 cases, the mutations were identical. In the case noted above, different mutations were present in the blood and urine culture isolates, after both mutations had been identified in the blood. The correlation of levels of phenotypic resistance and mutations in the CMV UL97 gene are summarized in table 2. Ninety percent of blood culture isolates and 56% of urine culture isolates with an IC 50 16.0 mM had a UL97 mutation (table   2) . The urine culture isolates with elevated IC 50 's without UL97 mutations had minimally elevated IC 50 's (16.0 mM but р8.2 mM). Ninety-seven percent of blood culture and 100% of urine culture isolates with an IC 50 18.0 mM had a UL97 mutation. Among patients treated with ganciclovir, 95% of blood culture and 60% of urine culture isolates with an IC 50 16.0 mM had a UL97 mutation. All blood culture and urine culture isolates with an IC 50 18.0 mM from patients treated with ganciclovir had a UL97 mutation. Ninety-nine percent of blood culture isolates and 100% of urine culture isolates with an IC 50 р6.0 mM for ganciclovir had no UL97 mutations. Ninety-five percent of blood culture isolates and 100% of urine culture isolates with a UL97 mutation had an IC 50 16.0 mM. Conversely, 98% of blood culture isolates without a UL97 mutation had an IC 50 р6.0 mM, and 100% had an IC 50 р12.0 mM. Ninety-five percent of urine culture isolates without a UL97 mutation had an IC 50 р6.0 mM, and 100% had an IC 50 !8.0 mM.
There was good phenotype-genotype correlation. If the occurrence of a UL97 mutation is considered to be the "gold standard" for resistance, then the sensitivity, specificity, and positive and negative predictive values for phenotypic resistance, on the basis of the IC 50 , can be calculated. For an IC 50 16.0 mM for ganciclovir from a blood culture isolate, the sensitivity is 95%, the specificity is 98%, and the positive and negative predictive values are 90% and 99%, respectively, for identifying an isolate with a UL97 mutation. For an IC 50 18.0 mM, the sensitivity is 79%, the specificity is 99%, and the positive and negative predictive values are 97% and 95%, respectively.
Conversely, if phenotypic resistance is assumed to be the "gold standard," then the sensitivity, specificity, and positive and negative predictive values for a UL97 mutation are 90%, 99%, 95%, and 98%, respectively, for an mM and 97%, 95%, IC 1 6.0 50 79%, and 99%, respectively, for an mM. For urine IC 1 8.0 50 culture isolates, similar numbers could be calculated, but the number of positive specimens was sufficiently small; therefore, these numbers are less reliable.
UL54 mutations. Ten separate mutations in the UL54 gene were identified, 6 of which were identified in the conserved region. The A987G (1 patient) and P522S (2 patients) mutations conferred ganciclovir resistance [11] . The V781I mutation (1 patient) conferred foscarnet resistance but not ganciclovir resistance [15] . The V787L, A692S, and A619T mutations (1 patient each) were associated with moderate levels of ganciclovir resistance (IC 50 , 10-20 mM) and may or may not have contributed to a ganciclovir-resistant phenotype. Two of the patients treated with ganciclovir each had 1 mutation in the UL54 gene in the nonconserved region (P116S and V902M), and 2 patients treated with cidofovir each had a mutation in the nonconserved region (A1154P and A1102T). The importance of these changes is uncertain. All 3 of the patients with isolates with both a UL97 and a confirmed resistance-conferring UL54 mutation had an IC 50 112.0 mM, and 2 of the 3 had an IC 50 130.0 mM. Of the 4 patients with an isolate with an mM, 2 had a confirmed resistance-conferring IC 1 30.0 50 UL54 mutation.
Discussion
We previously reported that 27% of patients treated with ganciclovir for 9 months developed a ganciclovir-resistant CMV isolate, defined phenotypically as an IC 50 16.0 mM [2, 3, 5] . In this study, we compared phenotypic and genotypic resistance. The major strengths of our study were that it was prospective and that we were able to obtain sequential isolates. However, there were limitations to our study. If CMV could not be isolated from blood or urine, the patient was assumed to harbor a phenotypically sensitive virus, and testing for genotypic resistance was performed only on specimens from a positive culture. Although these assumptions are reasonable, estimates of resistance are minimum estimates. Blood culture isolates can be evaluated directly for ganciclovir-conferring mutations by using PCR [9] , but this approach was not used, since the purpose of this study was to identify phenotype-genotype correlations.
Our data show good phenotype-genotype correlation. If the threshold for defining phenotypic resistance was chosen as 6.0 mM, the sensitivity and specificity for identifying a UL97 mutation for blood culture isolates were 95% and 98%, respectively, and if the threshold was 8.0 mM they were 79% and 99%, respectively. Drew et al. [2, 5] used the 6.0-mM threshold, whereas Smith et al. [10] used the 8.0-mM threshold. Our data suggest that either threshold is reasonable for blood culture isolates, with trade-offs in sensitivity, specificity, and positive and negative predictive values. For urine culture isolates, the 8.0-mM threshold may be better. Potential reasons for discrepancies between the phenotypic and genotypic results include both limitations in the mutation detection technology and phenotypic assay variability at borderline levels of resistance (IC 50 , 6.0-8.0 mM). PCR-based techniques will miss mutations not included a priori in the assay design, and sequencing analysis does not detect mutated viral populations when present in no more than 25%-30% of the total [16] . Our data suggest that phenotypic assay variability at borderline levels of resistance may be more of a problem for urine specimens than for blood specimens.
Phenotypic resistance gives a single measure of the level of resistance of the CMV isolated from the blood or urine. However, mixed populations of CMV may exist in an individual [16, 17] , and each subpopulation may have a different level of resistance. Although we did not evaluate the sensitivity of the Hybriwix assay for detecting the presence of resistant viruses in a mixed population, the plaque reduction assay typically detects 20%-25% of UL97 mutants in a background of wildtype virus (K. Biron, personal communication), and our quality control data have shown good correlation between the Hybriwix assay and the plaque reduction assay [5] . In general, patients who developed a resistant isolate and were continued on ganciclovir therapy developed increasing levels of phenotypic resistance over time (data not shown). Although the mutations identified usually were identical between the blood and urine isolates and tended to persist over time, mixed populations appeared to be present in a few patients. Change in therapy in 2 patients was associated with changes in the mutations detected, suggesting the emergence of resistant subpopulations in the context of a complex CMV population [15, 16] .
Smith et al. [10] reported good correlation between high-level phenotypic resistance to ganciclovir (IC 50 , 130 mM) and the presence of mutations in both the UL97 and UL54 genes. However, 2 patients in our series had high-level phenotypic resistance to ganciclovir but only had UL97 mutations. Reasons for this difference are unclear, but it suggests that high-level resistance to ganciclovir may occur without a UL54 mutation.
We identified 1 UL97 point mutation (H469Y) that has not been confirmed in marker-transfer experiments but probably contributed to ganciclovir resistance, given the level of resistance in the patient. Smith et al. [10] also found the H469Y mutation in 1 patient with phenotypic resistance to ganciclovir. We also identified a deletion of codons 600 and 601, which was associated with a high level of ganciclovir resistance; although this deletion (to the best of our knowledge) had not been identified previously, a larger deletion of codons 595-603 has been associated with ganciclovir resistance [11, 18] . Two of the 10 UL54 mutations conferred ganciclovir resistance, and 1 conferred foscarnet resistance but not ganciclovir resistance. The V787L, A692S, and A619T mutations, of which all were associated with moderate levels of ganciclovir resistance, have not been tested in marker-transfer experiments. These mutations may or may not contribute to a ganciclovir-resistant phenotype.
In conclusion, our data show good phenotype-genotype correlation for ganciclovir resistance, particularly among isolates derived from blood cultures. They provide a good estimate of the values of phenotypic thresholds for identifying genotypic resistance, confirm the phenotypic definitions of resistance used in previous studies, and demonstrate a good correlation between the blood and urine compartments. Because it is now possible to identify mutations directly from blood specimens by using PCR, it may be possible to more rapidly identify patients who harbor resistant virus without the need to isolate CMV from cultures.
